<DOC>
	<DOC>NCT01792635</DOC>
	<brief_summary>This study is designed to assess the safety, tolerability and pharmacodynamics of 6 weeks of oral doses of PF-05175157 provided as monotherapy in subjects with type 2 diabetes mellitus.</brief_summary>
	<brief_title>A 6-Week Study Of PF-05175157 In Type 2 Diabetes Mellitus</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<criteria>Subjects who have been diagnosed with type 2 diabetes mellitus by a medical professional according to the American Diabetes Association guidelines. Hemoglobin A1c of ≥7 and ≤10.0% in subjects who are metforminnaive or have not taken metformin for 2 months or Hemoglobin A1c of ≥6.5 and ≤9.5% in subjects who are metforminnaïve and are taking SU or DPPIVi which is washed off or taking metformin and are willing to discontinue metformin in a 8week washout period. Evidence or history of clinically significant hematological, renal, endocrine (other than T2DM and hypothyroidism), gastrointestinal, cardiovascular, pulmonary, hepatic, psychiatric or neurologic disease. A waist circumference which makes fitting imto the bore of the MR scanner impossible. Subjects with history of dry eye, known ocular or systemic disease that affect the sclera or cornea.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Type 2 Diabetes Mellitus</keyword>
	<keyword>Pharmacodynamics</keyword>
	<keyword>Safety &amp; Tolerability</keyword>
</DOC>